NCT05528419View on ClinicalTrials.gov

Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

June 1, 2026

Conditions
Atrial Fibrillation RecurrentHypertension
Interventions
DRUG

Sacubitril-valsartan

sacubitril valsartan 100mg initiated, and titrated to 200mg according to mean clinic blood pressure at 1-month follow-up

DRUG

Valsartan

valsartan 80mg initiated, and titrated to 160mg according to mean clinic blood pressure at 1-month follow-up

Trial Locations (1)

200025

Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER